If you have been reading about aggregation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| 分子类别 | 合成多肽 | 含非天然氨基酸与脂肪酸侧链 |
| 分子量 | 约 4.7 kDa | 多肽量级，精确值随计法而异 |
| 外观 | 白色至类白色冻干粉 | 常见冻干形态，供复溶使用 |
| 溶解性 | 易溶于水 | 复溶后为澄清至微乳光液体 |
| 常见同义词 | LY3437943 | 开发阶段使用的代号 |
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Micelles consist of a hydrophobic inner core surrounded by a hydrophilic outer shell that is exposed to a solvent, and their structures can be spheres, disks or wormlike assemblies. Micelles form spontaneously when the concentration is above a critical micelle concentration and temperature. Amphiphiles with an intermediate level of hydrophobicity prefer to assemble into bilayer vesicles. Vesicles are spherical, hollow, lamellar structures that surround an aqueous core. The hydrophobic moiety faces inwards and forms the inner section of the bilayer, and the hydrophilic moiety is exposed to the aqueous environment on the inner and outer surface. Micelle structures have a hydrophobic interior and hydrophilic exterior. There is normally a distinct relationship between the amphiphilic character of a peptide and its function in that the amphiphilic character determines the self-assembly properties, and in turn this is what gives the peptide its functionality. The level of amphiphilicity can vary significantly in peptides and proteins; as such they can display regions that are either hydrophobic or hydrophilic in nature. An example of this is the cylindrical structure of an α-helix, as it could contain a section of hydrophobic residues along one face of the cylinder and a hydrophilic section of residues on the opposite face of the cylinder. For β-sheet structures, the peptide chain can be composed of alternating hydrophilic and hydrophobic residues, so that the side chains of the residues are displayed on opposite faces of the sheet.
presented evidence that in natural S. cerevisiae populations clonal reproduction and selfing (in the form of intratetrad mating) predominate. In nature, the mating of haploid cells to form diploid cells is most often between members of the same clonal population and out-crossing is uncommon. Analysis of the ancestry of natural S. cerevisiae strains led to the conclusion that out-crossing occurs only about once every 50,000 cell divisions. These observations suggest that the possible long-term benefits of outcrossing (e.g. generation of diversity) are likely to be insufficient for generally maintaining sex from one generation to the next. Rather, a short-term benefit, such as recombinational repair during meiosis, may be the key to the maintenance of sex in S. cerevisiae. Some pucciniomycete yeasts, in particular species of Sporidiobolus and Sporobolomyces, produce aerially dispersed, asexual ballistoconidia.
A 2016 WHO report found that formaldehyde from second-hand vapor was around 20% greater compared to background air levels. Normal usage of e-cigarettes generates very low levels of formaldehyde. Different power settings reached significant differences in the amount of formaldehyde in the e-cigarette vapor across different devices. Later-generation e-cigarette devices can create greater amounts of carcinogens. Some later-generation e-cigarettes let users increase the volume of vapor by adjusting the battery output voltage. Depending on the heating temperature, the carcinogens in the e-cigarette vapor may surpass the levels of cigarette smoke. E-cigarettes devices using higher voltage batteries can produce carcinogens including formaldehyde at levels comparable to cigarette smoke. The later-generation and "tank-style" devices with higher voltages (5.0 V) could produce formaldehyde at comparable or greater levels than in cigarette smoke. A 2015 study hypothesized from the data that at high voltage (5.0 V), a user, "vaping at a rate of 3 mL/day, would inhale 14.4 ± 3.3 mg of formaldehyde per day in formaldehyde-releasing agents." The 2015 study used a puffing machine showed that a third-generation e-cigarette turned on to the maximum setting would create levels of formaldehyde between five and 15 times greater than with cigarette smoke.
dispersive replication A hypothetical mode of DNA replication in which the pairing of template strands and newly synthesized strands is not consistent within the same daughter molecule; i.e. each of the replicated daughter molecules is a heterogeneous mixture, with some segments composed of the original template strands and others composed of the newly synthesized strands. This process implies that the pairing of strands does not occur uniformly at all replication forks. Only the semiconservative mode of replication occurs naturally. See also conservative replication.
Sources: en.wikipedia.org
== Embryonic development == During embryo development in mice, CCN1 is highly expressed in the cardiovascular, skeletal, and neuronal systems. CCN1 knockout mice are embryonic lethal due to defects in cardiac septal morphogenesis, deficient blood vessel formation in placenta, and compromised vascular integrity. In Xenopus laevis, CCN1 is required for normal gastrulation and modulation of Wnt signaling.
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known And Loved) and other publications, Alexander Shulgin lists thiobuscaline's dose range as 60 to 120 mg orally and its duration as about 8 hours. Its onset is about 1 hour. The effects of thiobuscaline have been reported to include a "benign and beautiful experience which never quite popped into anything psychedelic", subtle threshold effects, a vague awareness of something, being in a "wonderful place spiritually" but with "some dark edges", it being "pleasant, but certainly not psychedelic", and body discomfort. No clear hallucinogenic effects were described. Thiobuscaline is listed as being 4 times more potent as a psychoactive drug than mescaline. Thiobuscaline produced perpetual threshold psychoactive effects that did not further increase across a wide dose range of 35 to 120 mg orally. Shulgin described it as "always the simple and ephemeral catalyst of euphoria without substance and without body". In addition, he said that it could not easily be classified, for instance as a psychedelic or stimulant. Instead, Shulgin likened thiobuscaline to Ariadne (4C-D), which he noted had been called an "antidepressant". He hypothesized that thiobuscaline might be beneficial for treatment of depression in certain people in the exact same way as Ariadne.
=== Spoon test === The spoon test, developed in 1964 by Ernest Bors, relies on assessment of the smooth movement of the convex side of a spoon along the surface of the patient's skin. In patients with sudomotor dysfunction, the spoon will slide in a smooth and uninterrupted fashion. Conversely, the spoon's movement in normal controls will be frequently interrupted by the presence of sweat on the skin. The spoon test is inexpensive, easy to perform, but subjective and not quantitative.
Sources: en.wikipedia.org
=== Recombinant human growth hormone (rHGH) === In 1981, the new American corporation Genentech, after collaboration with Kabi, developed and started trials of recombinant human growth hormone (rHGH) made by a new technology (recombinant DNA) in which human genes were inserted into bacteria so that they could produce unlimited amounts of the protein. Because this was new technology, approval was deferred as lengthy safety trials continued over the next four years. In 1985, four young adults in the U.S. having received NPA growth hormone in the 1960s developed CJD (Creutzfeldt–Jakob disease). The connection was recognized within a few months, and use of human pituitary GH rapidly ceased. Between 1985 and 2003, a total of 26 cases of CJD occurred in adults having received NPA GH before 1977 (out of 7700), comparable numbers of cases occurred around the world. By 2003 there had been no cases in people who received only GH purified by the improved 1977 methods. Discontinuation of human cadaver growth hormone led to rapid Food and Drug Administration approval of Genentech's recombinant human growth hormone, which was introduced in 1985 as Protropin in the United States. Although this previously scarce commodity was suddenly available in "bucketfuls", the price of treatment (US$10,000–30,000 per year) was the highest at the time. Genentech justified it by the prolonged research and development investment, orphan drug status, and a pioneering post-marketing surveillance registry for tracking safety and effectiveness (National Cooperative Growth Study).
British Military History – Including British Indian Army during WW2 The Indian Army 1900–1939. Archived 5 July 2019 at the Wayback Machine. The Indian Army Archived 24 March 2023 at the Wayback Machine – talk by Rob Lyman on WWII Indian Army at We Have Ways Festival
=== JAK-STAT signalling === Multiple elements of the Drosophila JAK-STAT signalling pathway bear direct homology to human JAK-STAT pathway genes. JAK-STAT signalling is induced upon various organismal stresses such as heat stress, dehydration, or infection. JAK-STAT induction leads to the production of a number of stress response proteins including Thioester-containing proteins (TEPs), Turandots, and the putative antimicrobial peptide Listericin. The mechanisms through which many of these proteins act is still under investigation. For instance, the TEPs appear to promote phagocytosis of Gram-positive bacteria and the induction of the toll pathway. As a consequence, flies lacking TEPs are susceptible to infection by toll pathway challenges.
== Uses == Acetamide is used as a plasticizer and an industrial solvent. Molten acetamide is good solvent with a broad range of applicability. Notably, its dielectric constant is higher than most organic solvents, allowing it to dissolve inorganic compounds with solubilities closely analogous to that of water. Acetamide has uses in electrochemistry and the organic synthesis of pharmaceuticals, pesticides, and antioxidants for plastics. It is a precursor to thioacetamide.
Sources: en.wikipedia.org
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。
天然肽类在体内容易被酶解并快速清除。脂肪酸侧链与非天然氨基酸可以延缓清除、降低酶解速率。修饰后的分子因此更适合较长间隔的给药安排。
公开资料主要来自临床阶段的报告与注册平台记录。这些材料提供的是阶段性信息，而非最终结论。完整的安全性与有效性数据仍在积累中。
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.